Home | About Us | Contact Us  
   
 
BACK TO INDEX
 
 
 
DAWN AC Anticoagulation Software E-Newsletter
   February 2008 
  IN THIS ISSUE
 
 
  • Dawn AC User Survey Results
  • Joint NPSA Established Reports for Dawn
  • INR Machines Recalled
  • Blood Tests in Kitchen Hall Cause Concern
  • Death Risk Increased for Cancer Patients taking Anemia Drugs
  •  

     

     

     

    Welcome to the February edition of the DAWN AC Anticoagulation Software E-Newsletter for 2008.

     
     
    Dawn AC User Survey Results
    We carried out a Dawn AC User Survey recently which covered areas of working such as the analysis of staffing, responsibilities, procedures and performance. We collected results from around 90 sites around the world, and made these available to participants. The following table shows some interesting key statistics found:
     
     
     
    STATISTICS:    
    Average number of patients managed by each healthcare professional UK: 726 USA: 342
    How is INR testing done? Lab Analysers: 63% Point of Care Devices: 37%
    Do you have a set of written procedures? Yes: 89% No: 11%
    Do you routinely carry out audits against these procedures? Yes: 60% No: 40%
    How are INRs entered into your system? Manual: 61% Automatic: 39%
    Are patients with poor INR control given extra education?

    Average hours of patient education given:

    Yes: 85%

    1.9 Hours

    No: 15% 

     

     
    If you have any comments or wish to provide any feedback on the Dawn AC survey results then please let us know at support@4s-dawn.com.
     
     
    NPSA Established Reports for Dawn AC version 6 systems now Available!
     
     
    We have now created a standard installation pack of reports for Dawn AC version 6 users, which give the statistics needed according to the NPSA guidelines for patients established on anticoagulants. If you would like these reports emailed through to you, then please email support@4s-dawn.com or contact us on 015395 63091 and we will send these out to you.

    INR Machines Recalled after Inconsistent Readings Given

     
    SmartCheck INR machines have been recalled recently by the makers Unipath after a study revealed that the meters were giving inconsistent INR readings.

    Unipath commmented that the SmartCheck machines 'did not produce equivalent performance to the claims in the product labelling'. The MHRA (Medicines and healthcare products regulatory agency) says that there have been 'no reported adverse incidents' but they will be issuing a medical device alert.

    To read more of this article, please follow the below link:
     
     

    Blood Tests in Hall Kitchen Cause Concern

     
    Concerns have been raised over patients having their blood tests taken in a village hall kitchen near Lincoln recently, according to the Lincolnshire Echo.

    One patient commented that he actually saw food on the worktops while he was having his blood taken at the community centre. He and other patients have expressed fears over the risk of possible infection by conducting the tests here.

    Mr. Kinnersley, 73, said "the last time I was there there was food on the side and another guy made a joke about getting a sandwich afterwards. It would be logical to have it in the surgery and my GP thinks so too. It is fairly obvious to me that it is held in the community centre to cut costs".

    The NHS authorities deny this claim.

    To read more of this article, please follow the link to the newspaper below:
     
     

    Death Risk Increased with Blood Clots for Cancer Patients on Anemia Drugs & A New Dawn Anemia Application

     
     
    U.S. Researchers confirmed recently that giving cancer patients anemia drugs heightens their risk of blood clots and ultimately death.
     
    Researchers found that the risk of death in patients was increased by 10 percent when taking the anemia drugs (including Procrit by Johnson & Johnson and Aranesp by Amgen Inc.). Dr. Charles Bennett from the University of Chicago commented, "Our findings, in conjunction with basic science studies, raise the concern that the drug may be stimulating cancer and shortening cancer patients' survival".
     
    The advisory group to the FDA (Food and Drug Administration) in the USA is now planning to discuss these safety issues on the 13th of March.
     
    To read more of this article, please follow this link:
     

    We now have a new Dawn Anemia application to track patients on anemia drugs, detecting and flagging up out of line results. This application can aid the management and treatment of these patients. If you would like more information on this application or have any questions, then please contact us at

     

     
     
    Phone: +44 (0) 15395 63091